Inhibition of Glycolysis in Prostate Cancer Chemoprevention by Phenethyl Isothiocyanate

We have shown previously that dietary administration of phenethyl isothiocyanate (PEITC), a small molecule from edible cruciferous vegetables, significantly decreases the incidence of poorly differentiated prostate cancer In Transgenic Adenocarcinoma of Mouse Prostate (TRAMP) mice without any side effects. In this study, we investigated the role of c-Myc-regulated glycolysis in prostate cancer diemoprevention by PEITC. Exposure of LNCaP (androgen-responsive) and 22Rvl (castration-resistant) human prostate cancer cells to PEITC resulted In suppression of expression as well as transcriptional activity of c-Myc. Prostate cancer cell growth Inhibition by PEITC was significantly attenuated by stable overexpression of c-Myc. Analysis of the RNA-Seq data from The Cancer Genome Atlas indicated a significant positive association between Myc expression and gene expression of many glycolysis-related genes, includ ing hexoidnase II and lactate dehydrogenase A. Expression of these enzyme proteins and lactate levels were decreased upon PEITC treatment in prostate cancer cells, and these effects were significantly attenuated by ectopic expression of c-Myc, A normal prostate stromal cell line (PrSC) was resistant to lactic add suppression by PEITC treatment. Prostate cancer chemoprevention by PEITC in TRAMP mice was associated with a significant decrease in plasma lactate and pyruvate levels. However, a 1-week intervention with 10 mg PEITC (orally, 4 times/day) was not sufficient to decrease lactate levels in the serum of human subjects. These results Indicated that although prostate cancer prevention by PEITC In TRAMP mice was associated with suppression of glycolysis, longer than 1-week intervention might be necessary to observe such an effect in human subjects. (C)2018 AACR.